Millennium Medical Devices inks another network selling agreement
Published on April 9, 2014 at 9:09 AM
Millennium HealthCare Inc. (MHCC) today announced that its subsidiary, Millennium Medical Devices LLC, has signed yet another network selling agreement. This agreement was signed with a US based healthcare organization for the use of Millennium's medical devices in 400 of the organization's locations. This agreement includes an average monthly minimum use of 350 units per device, per location.
The network selling agreement includes the use of the VasoScan cardiovascular assessment test. The Company has exclusive distribution rights for the VasoScan device. VasoScan is an FDA cleared, non-invasive device that provides a reproducible assessment of arterial elasticity and stiffness, which determines plaque levels in the arterial walls. Plaque buildup in the arteries can cause cardiovascular disease and inhibit blood flow to major organs causing heart attack and stroke. Millennium Medical Devices maintains the exclusive rights to market and distribute the VasoScan device in the United States.
The network selling agreement also includes the use of the OralCDx Brush Biopsy Test Kit. The Company's has exclusive distribution rights for the device. OralCDx is a non-invasive test that is used to test the small white and red tissue spots commonly found in the mouth to rule out precancerous change. According to the oral cancer foundation, close to 42,000 Americans will be diagnosed with oral and oropharyngeal cancers this year. This disease will cause over 8,000 deaths. The test has previously been available to dentists nationwide, and has already resulted in the prevention of thousands of oral cancers. Through the exclusive distribution agreement with Millennium Medical Devices, primary care physicians will now be able to easily administer this test to their patients.
"Being able to detect disease for early intervention could potentially help the over 800,000 people alone (according to the CDC) who die annually from cardiovascular disease in the United States," said Dominick Sartorio, CEO of Millennium.
"There are over 250,000 primary care physicians in the United States who could utilize these tests in their practices. We anticipate that a majority of the 400 locations under contract will be operational within the next 18 months and we will continue to introduce VasoScan and OralCDx as quickly as we can, utilizing the contracted model. We feel that this sales model can assist investors in easily understanding the opportunities we have through these exclusive distribution relationships. Based on the minimum contracted amounts within the signed network selling agreements, Millennium can be in a position to potentially exceed $200,000,000 in revenues annually." The signing of another selling agreement further supports the Millennium model of distribution and the Company anticipates the device usage to increase as the delivery of product becomes more standardized.
Millennium HealthCare Inc.